Pacritinib

Last updated

Pacritinib
Pacritinib skeletal.svg
Clinical data
Trade names Vonjo
Other namesSB1518
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
  • (16E)-11-[2-(1-Pyrrolidinyl)ethoxy]-14,19-dioxa-5,7,26-triazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
Formula C28H32N4O3
Molar mass 472.589 g·mol−1
3D model (JSmol)
  • c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5
  • InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+
  • Key:HWXVIOGONBBTBY-ONEGZZNKSA-N

Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. [1] [2] [3] [4]

Contents

It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).

Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs. [2]

Medical uses

Pacritinib in indicated to treat adults who have a rare form of a bone marrow disorder known as intermediate or high-risk primary or secondary myelofibrosis and who have platelet (blood clotting cells) levels below 50,000/μL. [1] [2]

History

The effectiveness and safety of pacritinib were demonstrated in a study that included 63 participants with intermediate or high-risk primary or secondary myelofibrosis and low platelets who received pacritinib 200 mg twice daily or standard treatment. [2] Effectiveness was determined based upon the proportion of participants who had a 35% or greater spleen volume reduction from baseline to week 24. [2] Nine participants (29%) in the pacritinib treatment group had a 35% or greater spleen volume reduction, compared to one participant (3%) in the standard treatment group. [2]

The U.S. Food and Drug Administration (FDA) granted the application for pacritinib priority review, fast track, and orphan drug designations. [2] [5]

Society and culture

Names

Pacritinib is the International nonproprietary name (INN). [6] [7]

References

  1. 1 2 3 "Vonjo- pacritinib capsule". DailyMed. 7 March 2022. Retrieved 24 March 2022.
  2. 1 2 3 4 5 6 7 8 "FDA approves drug for adults with rare form of bone marrow disorder". U.S. Food and Drug Administration. 1 March 2022. Archived from the original on 1 March 2022. Retrieved 3 March 2022.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  3. ↑ Mascarenhas J (August 2022). "Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia". Expert Review of Hematology. 15 (8): 671–684. doi:10.1080/17474086.2022.2112565. PMID   35983661.
  4. ↑ Yang DH, Lu Q, Zhu Z, Huang G, Young K (December 2022). "Pacritinib for myelofibrosis in adults with thrombocytopenia". Drugs of Today. 58 (12): 577–589. doi:10.1358/dot.2022.58.12.3474538. PMID   36651066.
  5. ↑ Lamb YN (May 2022). "Pacritinib: First Approval". Drugs. 82 (7): 831–838. doi:10.1007/s40265-022-01718-y. PMID   35567653.
  6. ↑ World Health Organization (2010). "International nonproprietary names for pharmaceutical substances (INN). proposed INN: list 104" (PDF). WHO Drug Information. 24 (4): 386. hdl: 10665/74579 .
  7. ↑ World Health Organization (2011). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 66". WHO Drug Information. 25 (3). hdl: 10665/74683 .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.